Neuroscience Antibodies and Assays Market Overview - Leading Players and Business Intelligence
Growth in this market is driven by the rising incidence of
neurological diseases, increasing investments in neuroscience research,
and growth in the pharmaceutical and biotechnology industries. On the
other hand, quality and cost concerns over the production of antibodies
are the major factor restraining the growth of this market.
According to research report the Neuroscience Antibodies Market is expected to reach USD 4.18 Billion by 2023 from USD 2.57 Billion in 2018, at a CAGR of 10.2%.
Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=129888612
The Neuroscience Antibodies Market are segmented based on product, technology, application, end user, and region.
•
Based on product, the Neuroscience Antibodies Market are segmented into
consumables and instruments. The consumables segment is expected to
account for the largest market share in 2018 and is expected to register
the highest CAGR during the forecast period.
• Based on end user,
the Neuroscience Antibodies Market are segmented into pharmaceutical and
biotechnology companies, academic and research institutes, and
hospitals and diagnostic centres.
• Based on type, the consumables
market is segmented into reagents, antibodies, and assays kits. The
reagents segment is expected to account for the largest share in 2018.
The large share of this segment is attributed to the high consumption of
reagents in various routine assays and techniques.
• Based on
technology, the Neuroscience Antibodies Market are segmented into
immunoassays/immunochemistry, molecular diagnostics, clinical chemistry,
and other technologies.
The neuroscience antibodies and assays
market is fragmented, with the presence of several large as well as
emerging players. In 2017, Thermo Fisher Scientific (US), Abcam (UK),
Bio-Rad (US), and Merck KGaA (Germany) were the leading players in the
neuroscience antibodies and assays market. Other major players include
BioLegend (US), Cell Signaling Technology (US), F. Hoffmann-La Roche
(Switzerland), GenScript (China), Rockland Immunochemicals (US), Santa
Cruz Biotechnology (US), Siemens (Germany), and Tecan (Switzerland).
Agreements,
partnerships, and collaborations accounted for the largest share of the
overall growth strategies followed by key players between 2015 and
2018. Some of the companies that adopted this strategy include Cell
Signaling Technology (US), Abcam (UK), Rockland Immunochemicals (US),
BioLegend (US), Tecan (Switzerland), and Merck KGaA (Germany).
Thermo
Fisher Scientific (US) is one of the prominent players in the
neuroscience antibodies and assays market. This leading position of the
company can be attributed to its strong brand recognition and extensive
product portfolio in the neuroscience antibodies and assays market.
Abcam
(UK) accounted for the second largest share of the neuroscience
antibodies and assays market in 2017. The company offers a broad range
of solutions for the neuroscience industry, which include primary
antibodies, proteins and peptides, agonists, activators, antagonists and
inhibitors, ELISA, matched antibody pairs and multiplex immunoassays,
lysates, and cellular & biochemical assays.
Get Sample Report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=129888612
Among
the four regional segments, Asia is expected to grow at the highest
CAGR during the forecast period. The high growth in the Asian market is
attributed to factors such as favourable regulatory guidelines, rising
incidence of neurological diseases, growing presence of market players
in emerging economies, and favourable government investments in the life
sciences sector.
Comments
Post a Comment